148 related articles for article (PubMed ID: 25319392)
1. Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer.
Guerrouahen BS; Pasquier J; Kaoud NA; Maleki M; Beauchamp MC; Yasmeen A; Ghiabi P; Lis R; Vidal F; Saleh A; Gotlieb WH; Rafii S; Rafii A
Mol Cancer Ther; 2014 Dec; 13(12):3123-36. PubMed ID: 25319392
[TBL] [Abstract][Full Text] [Related]
2. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
[TBL] [Abstract][Full Text] [Related]
3. Akt-activated endothelium promotes ovarian cancer proliferation through notch activation.
Hoarau-Véchot J; Touboul C; Halabi N; Blot-Dupin M; Lis R; Abi Khalil C; Rafii S; Rafii A; Pasquier J
J Transl Med; 2019 Jun; 17(1):194. PubMed ID: 31182109
[TBL] [Abstract][Full Text] [Related]
4. Direct effect of bevacizumab on glioblastoma cell lines in vitro.
Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP
Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866
[TBL] [Abstract][Full Text] [Related]
5. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.
Gyanchandani R; Ortega Alves MV; Myers JN; Kim S
Mol Cancer Res; 2013 Dec; 11(12):1585-96. PubMed ID: 24092775
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
7. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
8. miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.
Wuerkenbieke D; Wang J; Li Y; Ma C
Arch Gynecol Obstet; 2015 Nov; 292(5):1109-16. PubMed ID: 25986891
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
10. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
11. IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment.
Kinose Y; Sawada K; Makino H; Ogura T; Mizuno T; Suzuki N; Fujikawa T; Morii E; Nakamura K; Sawada I; Toda A; Hashimoto K; Isobe A; Mabuchi S; Ohta T; Itai A; Morishige K; Kurachi H; Kimura T
Mol Cancer Ther; 2015 Apr; 14(4):909-19. PubMed ID: 25637316
[TBL] [Abstract][Full Text] [Related]
12. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
13. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
14. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
16. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M
Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
Martin L; Schilder R
J Clin Oncol; 2007 Jul; 25(20):2894-901. PubMed ID: 17617520
[TBL] [Abstract][Full Text] [Related]
19. Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.
Guo H; Zhu Q; Yu X; Merugu SB; Mangukiya HB; Smith N; Li Z; Zhang B; Negi H; Rong R; Cheng K; Wu Z; Li D
Oncogene; 2017 Sep; 36(36):5098-5109. PubMed ID: 28481872
[TBL] [Abstract][Full Text] [Related]
20. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
